This study has some limitations: (i) it is a small retrospective analysis of a prospective cohort, thus subject to residual confounding; (ii) it included different tumor types (being breast cancer the most predominant); and (iii) expression of FGF23 in metastatic tissue was not assessed. This evidence concerns the gene FGF23 and breast cancer.